A Phase 2, Multicenter, International Single Arm Study to Assess the Safety and Efficacy of Single Agent CC-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Azacitidine (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 03 Jun 2017 This trial has been completed in Spain (end date: 20 Apr 2017).
- 28 May 2017 This trial has been completed in Spain (end date: 20 Apr 2017).
- 05 Apr 2017 Planned End Date changed from 1 Mar 2017 to 15 Jun 2017.